Bellerophon’s New Scientific Board to Focus on PH Device

Bellerophon’s New Scientific Board to Focus on PH Device

Bellerophon Therapeutics, Inc. has established a new INOpulse Scientific Advisory Board (SAB) to help develop its proprietary novel technology to treat pulmonary hypertension (PH). The board includes internationally recognized specialists in the disease who will work in collaboration with the company’s medical team.

Bellerophon’s SAB and medical team will jointly work on the development of the company’s inhaled nitric oxide drug-device, called INOpulse, a technology meant to help treat PH patients. “Creation of the INOpulse Scientific Advisory Board underscores our commitment to the development of our technology in pulmonary hypertension for chronic outpatient use to benefit patients with various forms of this debilitating disease,” stated Bellerophon’s chairman and CEO, Jonathan Peacock.

“We are especially pleased to have such a distinguished group of thought leaders working with us to broaden and advance our programs in PH. The participation of these distinguished SAB members reflects the advances we have made in our clinical programs in the past year, and will help us define and advance our programs in the next few years,” added Peacock in a press release.

The INOpulse SAB will include the medical director of the Pulmonary Hypertension Center, chairman of the Department of Medicine at Intermountain Medical Center and professor of Medicine at the University of Utah, Greg Elliot, MD, MACP, the head of the Pulmonary Hypertension Center at the University of Bologna, Nazzareno Galie, MD, and the associate professor for Internal Medicine and head of the Pulmonary Hypertension Division at University Hospital, Giessen, Ardeschir Ghofrani, MD.

Fernando Martinez, MD, who is the executive vice chair of Medicine at the Weill Cornell Medical College and New York-Presbyterian Hospital/Weill Cornell Medical Center, will also be one of the members, alongside with Vallerie McLaughlin, MD, professor of Medicine and director of the Pulmonary Hypertension Program at the University of Michigan, and Robert Naeije, MD, PhD, professor and chairman of the Department of Physiology and Pathophysiology at Erasme University Hospital in Brussels.

[adrotate group=”4″]

In addition, the professor of Medicine in the Pulmonary and Critical Care Medicine, Department of Internal Medicine at the University of Nebraska Medical Center in Omaha, Steve Rennard, MD, the emeritus professor of Medicine and emeritus director of Pulmonary and Critical Care at the University of California in San Diego, Lewis Rubin, MD, and the professor of Respiratory Medicine at the South Paris University, Olivier Sitbon, MD, PhD, will also serve as members.

The company is currently planning to evaluate the technology in two clinical studies. The first of them, a phase 3 trial to be initiated later in the year, is focused on the use of INOpulse in patients with pulmonary arterial hypertension, while the other, a phase 2b trial, will assess the technology in patients with PH associated to chronic obstructive pulmonary disease (COPD).

Leave a Comment